Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evenamide add-on phase III trial in treatment-resistant schizophrenia
2024-519836-18-00Phase 3Authorised
- Sponsor
- Newron Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of evenamide in schizophrenia (3 arms), sponsored by Newron Pharmaceuticals. Primary endpoint: Change from baseline to Week 12 in PANSS total score. Planned start Dec 2025; status: authorised.
02
Drugs
evenamide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2024-519836-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519836-18-00.